aphranel® Hosts European Physicians in China for Clinical Exchange Programme

aphranel®, the regenerative aesthetics brand of MOYOM Biotech, launched a week-long clinical exchange programme bringing European physicians to China for clinical observation and discussion. The initiative, part of a global academic programme named The Norns' Weave, focuses on comparing Chinese clinical practice with potential applications in Europe under the theme "Learning in China, Applying in Europe."

According to reported details, the programme involves multi-city site visits, case discussions, and injection demonstrations. Verification of these activities can be conducted through official company announcements and medical academic conference disclosures.

Programme Overview and Objectives

• Initiative: The Norns' Weave global academic programme
• Participant Focus: European physicians visiting Chinese aesthetic medical facilities
• Core Themes: Dialogue, Exchange, and Convergence in regenerative aesthetics

Clinical Visits and Activities

Participating medical professionals visited several facilities across multiple cities, engaging in practical discussions regarding facial aesthetic assessments and individualised treatment planning.

• Locations Visited: Facilities in Guangzhou, Shenzhen, Shanghai, and Hangzhou, including Yestar Medical Aesthetic Hospital and Shenzhen Boai Shuguang Hospital.
• Clinical Topics: CaHA-based facial biostructuring, anatomical differences, injection depths, and preserving natural facial expressions.

Background and Future Plans

aphranel® draws on more than 12 years of research and development, following regulatory approvals including NMPA Class III medical device approval in China in 2025 and EU MDR certification in 2026. MOYOM Biotech plans to extend The Norns' Weave through further European academic exchanges, Expert-to-Expert collaborations, and ongoing clinical evidence development.